Back to Browse Journals » Vascular Health and Risk Management » Volume 5

The management of gestational diabetes

Authors N Wah Cheung

Published 15 January 2009 Volume 2009:5 Pages 153—164


Review by Single-blind

Peer reviewer comments 2

N Wah Cheung

Centre for Diabetes and Endocrinology Research, Westmead Hospital, and University of Sydney, NSW, Australia

Abstract: The incidence of gestational diabetes is increasing. As gestational diabetes is associated with adverse pregnancy outcomes, and has long-term implications for both mother and child, it is important that it is recognized and appropriately managed. This review will examine the pharmacological options for the management of gestational diabetes, as well as the evidence for blood glucose monitoring, dietary and exercise therapy. The medical management of gestational diabetes is still evolving, and recent randomized controlled trials have added considerably to our knowledge in this area. As insulin therapy is effective and safe, it is considered the gold standard of pharmacotherapy for gestational diabetes, against which other treatments have been compared. The current experience is that the short acting insulin analogs lispro and aspart are safe, but there are only limited data to support the use of long acting insulin analogs. There are randomized controlled trials which have demonstrated efficacy of the oral agents glyburide and metformin. Whilst short-term data have not demonstrated adverse effects of glyburide and metformin on the fetus, and they are increasingly being used in pregnancy, there remain long-term concerns regarding their potential for harm.

Keywords: gestational diabetes, insulin, oral antidiabetic agents, pregnancy, type 2 diabetes

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Prolonged increase in tear meniscus height by 3% diquafosol ophthalmic solution in eyes with contact lenses

Nagahara Y, Koh S, Nishida K, Watanabe H

Clinical Ophthalmology 2015, 9:1029-1031

Published Date: 9 June 2015

Linagliptin as add-on therapy to insulin for patients with type 2 diabetes

von Websky K, Reichetzeder C, Hocher B

Vascular Health and Risk Management 2013, 9:681-694

Published Date: 1 November 2013

Functionalized carbon nanotubes: biomedical applications

Vardharajula S, Ali SZ, Tiwari PM, Eroğlu E, Vig K, Dennis VA, Singh SR

International Journal of Nanomedicine 2012, 7:5361-5374

Published Date: 9 October 2012

Development of 3D in vitro platform technology to engineer mesenchymal stem cells

Hosseinkhani H, Hong P, Yu D, Chen Y, Ickowicz D, Farber I, Domb AJ

International Journal of Nanomedicine 2012, 7:3035-3043

Published Date: 29 June 2012

Adult-onset bulbar ptosis in Joubert syndrome

Burt B, Levine J, Le K

Clinical Ophthalmology 2012, 6:151-153

Published Date: 24 January 2012

Preparation, characterization, and in vivo evaluation of a self-nanoemulsifying drug delivery system (SNEDDS) loaded with morin-phospholipid complex

Zhang J, Peng Q, Shi S, Zhang Q, Sun X, Gong T, Zhang Z

International Journal of Nanomedicine 2011, 6:3405-3414

Published Date: 19 December 2011

Update on the clinical use of the low-molecular-weight heparin, parnaparin

Giuseppe Camporese, Enrico Bernardi, Franco Noventa

Vascular Health and Risk Management 2009, 5:819-831

Published Date: 25 September 2009

The role of insulin detemir in overweight type 2 diabetes management

Yared N Demssie, Naveed Younis, Handrean Soran

Vascular Health and Risk Management 2009, 5:553-560

Published Date: 29 June 2009

Arterial stiffness in insulin resistance: The role of nitric oxide and angiotensin II receptors

Divina G Brillante, Anthony J O’Sullivan, Laurence G Howes

Vascular Health and Risk Management 2009, 5:73-78

Published Date: 4 December 2008